Sciences 2023 Breakthrough: GLP-1 Agonists Show Promise Against Obesity-Associated Disease. American Association for the Advancement of Science (AAAS)
Preliminary findings suggest that these drugs may have even more unexpected off-label uses, such as helping to reduce alcohol use disorder (AUD) , reduce high blood pressure (hypertension) , and provide defense against heart disease and even dementia
The concern is what happens when manufacturers control the prescribing pathway directly
Many times, you dont even have the full ingredient list on hand, nor do you have any idea where they were manufactured and under what levels of quality control.Combine that with a lack of formal studies or obligation to disclose side effects, and its difficult to know what you may be getting into
Morton points to retatrutide, a weekly injection from Eli Lilly currently in clinical development for obesity and type 2 diabetes, as an example
[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Puig L